Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study

(Reuters) - Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.

Source: Reuters: Health - February 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news